Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metformin--an update

C J Bailey1

  • 1Department of Pharmaceutical Sciences, Aston University, Birmingham, England.

General Pharmacology
|November 1, 1993
PubMed
Summary
This summary is machine-generated.

Metformin, an antihyperglycemic drug, improves insulin sensitivity by increasing glucose uptake and reducing glucose production in type 2 diabetes. It offers benefits like lower triglycerides and minimal risk of hypoglycemia or weight gain when used appropriately.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future.

Clinical pharmacology and therapeutics·2015
Same author

Safety of antidiabetes medications: An update.

Clinical pharmacology and therapeutics·2015
Same author

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.

Diabetic medicine : a journal of the British Diabetic Association·2014
Same author

Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials.

Diabetes, obesity & metabolism·2014
Same author

A cotyledon slice system for the electron autoradiographic study of the synthesis and intracellular transport of the seed storage protein of Vicia faba.

Planta·2014
Same author

Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.

Diabetes, obesity & metabolism·2012
Same journal

Endothelium-dependent vasorelaxant and antiproliferative effects of apigenin.

General pharmacology·2002
Same journal

Reversal of hypercapnia induces endothelin-dependent constriction of basilar artery in rabbits with acute metabolic alkalosis.

General pharmacology·2002
Same journal

Reversal of hypercapnia induces KATP channel and NO-independent constriction of basilar artery in rabbits with acute metabolic alkalosis.

General pharmacology·2002
Same journal

Contractile responses in spontaneously diabetic mice. II. Effect of cholestyramine on enhanced contractile response of aorta to norepinephrine in C57BL/KsJ (db/db) mice.

General pharmacology·2002
Same journal

Contractile responses in spontaneously diabetic mice. I. Involvement of superoxide anion in enhanced contractile response of aorta to norepinephrine in C57BL/KsJ(db/db) mice.

General pharmacology·2002
Same journal

Investigation of basal endothelial function in the obese Zucker rat in vitro.

General pharmacology·2002
See all related articles

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Metformin (dimethylbiguanide) is a primary oral antihyperglycemic agent for type 2 diabetes.
  • It addresses insulin resistance by enhancing glucose utilization and reducing hepatic glucose production.

Purpose of the Study:

  • To elucidate the multifaceted mechanisms of action of metformin.
  • To detail its effects on glucose metabolism, insulin signaling, and other physiological parameters.

Main Methods:

  • Review of existing pharmacological and clinical data on metformin's effects.
  • Analysis of metformin's impact on insulin postreceptor pathways and glucose transporter activity.

Main Results:

  • Metformin enhances glucose uptake, oxidation, and glycogenesis in muscle.

Related Experiment Videos

  • It increases intestinal glucose metabolism to lactate and reduces hepatic gluconeogenesis.
  • Metformin facilitates postreceptor insulin signaling and glucose transporter translocation, with minimal risk of hypoglycemia or weight gain.

    • Conclusions:

    • Metformin effectively manages hyperglycemia in type 2 diabetes by improving insulin sensitivity.
    • Additional benefits include antihypertriglyceridemic and hemostatic effects.
    • Risk of lactic acidosis is minimal when contraindications, such as renal impairment, are observed.